LEXX — Lexaria Bioscience Cashflow Statement
0.000.00%
Last trade - 00:00- $23.70m
- $16.78m
- $0.46m
Annual cashflow statement for Lexaria Bioscience, fiscal year end - August 31st, USD millions except per share, conversion factor applied.
C2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.08 | -4.19 | -7.38 | -6.71 | -5.81 |
| Depreciation | |||||
| Non-Cash Items | 1.55 | 0.021 | 2.75 | 0.543 | 0.667 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.194 | 0.064 | -0.351 | 0.143 | 0.107 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -2.62 | -3.99 | -4.88 | -5.88 | -4.96 |
| Capital Expenditures | -0.034 | -0.079 | -0.181 | -0.17 | -0.189 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.007 | 0.273 | — | — | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | -0.027 | 0.194 | -0.181 | -0.17 | -0.189 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.65 | 13.4 | -0.045 | 1.59 | 10.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.009 | 9.62 | -5.1 | -4.46 | 5.15 |